Type 1 plasminogen activator inhibitor (PAI-1) in clear cell renal cell carcinoma (CCRCC) and its impact on angiogenesis, progression and patient survival after radical nephrectomy

BACKGROUND: To examine the expression of type 1 plasminogen inhibitor (PAI-1) in clear cell renal cell carcinoma (CCRCC), and its possible association with microvessel density (MVD), the expression of thrombospondin-1 (TSP-1), nuclear grade, tumour stage, continuously coded tumour size (CCTS) and to...

Descripción completa

Detalles Bibliográficos
Autores principales: Zubac, Dragomir P, Wentzel-Larsen, Tore, Seidal, Tomas, Bostad, Leif
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3002359/
https://www.ncbi.nlm.nih.gov/pubmed/21129210
http://dx.doi.org/10.1186/1471-2490-10-20

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3002359/
https://www.ncbi.nlm.nih.gov/pubmed/21129210
http://dx.doi.org/10.1186/1471-2490-10-20

Ejemplares similares